Bone growth compositions and methods
AssigneeNeuropro Technologies, Inc.
InventorsBenjamin J. Remington, David J. Bearss, Kavian Shahi
Life of this patent
Estimating the term…
Abstract
The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.
Claims63
A method for enhancing non-anatomic bone formation in a site, the method comprising the steps of administering an HMG-CoA reductase inhibitor to the site.
A method for promoting spinal fusion, the method comprising the steps of:
- exposing an upper vertebra and a lower vertebra;
- identifying a site for fusion between the upper and the lower vertebra;
- exposing a bony surface on each of the upper and the lower vertebra at the site for fusion;
- applying an HMG-CoA reductase inhibitor to a carrier;
- applying the carrier to one of the exposed bony surfaces at the site.
A method of promoting non-anatomical bone growth between two bony surfaces, the method comprising the steps of:
- identifying a site between two bony surfaces where bone growth is desired but does not naturally occur;
- exposing bone at each of the two bony surfaces;
- applying an HMG-CoA reductase inhibitor to at least one of the bony surfaces.
A method for fixation of maxillary and mandibular osteotomies comprising:
- identifying a site for fusion between a maxillary bone and a mandibular bone;
- exposing a bony surface at each of the two bones;
- applying an HMG-CoA reductase inhibitor to at least one of the bony surfaces.
A method for treating ankle arthritis comprising
- identifying bones on either side of an affected joint;
- exposing bony surface on each of the bones;
- applying an HMG-CoA reductase inhibitor to at least one of the bony surfaces.
A carrier for enhancing bone formation wherein said carrier comprises an HMG-CoA reductase inhibitor.
The carrier of claim 61 wherein the carrier further comprises an antibiotic, a pain medication, a growth hormone or a combination thereof.
Dependencies are inferred from the claim text.